Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension study of enzalutamide in prostate cancer patients previously treated in an enzalutamide clinical trial
MOH_2018-01-04_002085Phase 2Not yet recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2018-01-04_002085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-04_002085.